BioSpace News Archive

Co-Diagnostics, Inc. announced today the completion of a sales and validation trip to the Dominican Republic, including the initiation of a vector control diagnostics program to track the spread and distribution of tropical diseases across mosquito populations.

Varian today announced that it will webcast a conference call to discuss the details of the agreement, also announced today, to acquire all the outstanding shares of Sirtex Medical.

Mazor Robotics announced today that it will report financial results for the fourth quarter and full year ended December 31, 2017, before the U.S. markets open on Wednesday, February 14, 2018.

The Company is expanding its direct sales and support activity in North America, having recently opened a sales and support operation in New Jersey, and has established a network of distributors in Europe and the Far East to support the launch of its integrated Cyto-Mine Single Cell Analysis System.

Skin Biology Inc. today announced that they have received US patent 9,586,989 for “Non-toxic skin cancer therapy with copper peptides”. The patent describes a method to biologically remove basal skin cancers in humans and melanomas in horses.

Humanetics Corporation has recently completed two research studies funded by the National Aeronautics and Space Administration and the National Space Biomedical Research Institute, which evaluated the potential of Humanetics’ investigational drug, BIO 300, to mitigate the toxicities from space-like radiation exposure.

Elite intends to review with the FDA the study results and discuss the pharmacokinetic study requirements for a re-submission of the NDA.

He joins Synteract from Chiltern, a Covance company, where he was vice president, Global Business Development Biopharma.

ccRCC is diagnosed in over 200,000 patients worldwide each year and the number of people affected continues to increase.

CymaBay anticipates using the net proceeds from the offering to fund ongoing development of seladelpar and for working capital and general corporate purposes.